X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
Details:
The partnership aims to assist in the commercialization of Rigel Pharmaceuticals' approved product, Gavreto (pralsetinib), which is indicated for RET fusion-positive non-small cell lung cancer.
Lead Product(s): Pralsetinib
Therapeutic Area: Oncology Product Name: Gavreto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Rigel Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 27, 2024
Details:
Through the acquisition, Rigel will able to commercialize the Gavreto (pralsetinib), which is an FDA-approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer.
Lead Product(s): Pralsetinib
Therapeutic Area: Oncology Product Name: Gavreto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Rigel Pharmaceuticals
Deal Size: $117.5 million Upfront Cash: Undisclosed
Deal Type: Acquisition February 22, 2024
Details:
Under the terms of the agreement, Blueprint Medicines will regain global commercialization and development rights to Gavreto (pralsetinib), a once-daily oral targeted therapy, excluding Greater China.
Lead Product(s): Pralsetinib
Therapeutic Area: Oncology Product Name: Gavreto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $1,702.0 million Upfront Cash: $775.0 million
Deal Type: Termination February 23, 2023
Details:
Gavreto (pralsetinib) is a kinase inhibitor of wild-type RET and oncogenic RET fusions (CCDC6-RET) and mutations. It is approved for adult patients with locally advanced or metastatic RET fusion-positive NSCLC or thyroid cancer and advanced or metastatic RET-mutant MTC.
Lead Product(s): Pralsetinib
Therapeutic Area: Oncology Product Name: Gavreto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
GAVRETO is an important precision therapy that has been incredibly meaningful for patients with metastatic, RET fusion-positive non-small cell lung cancer who may have otherwise had limited options.
Lead Product(s): Pralsetinib
Therapeutic Area: Oncology Product Name: Gavreto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Royalty Pharma
Deal Size: $340.0 million Upfront Cash: $175.0 million
Deal Type: Collaboration June 30, 2022
Details:
Preclinical data have shown that Gavreto inhibits primary RET fusions and mutations that cause cancer in subsets of patients, as well as secondary RET mutations predicted to drive resistance to treatment.
Lead Product(s): Pralsetinib
Therapeutic Area: Oncology Product Name: Gavreto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2021
Details:
Gavreto® (pralsetinib) is approved once-daily, oral targeted treatment designed to selectively target rearranged during transfection (RET) alterations. Gavreto showed robust and durable clinical responses in people with NSCLC with RET fusions.
Lead Product(s): Pralsetinib
Therapeutic Area: Oncology Product Name: Gavreto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Blueprint Medicines
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2021
Details:
Pralsetinib showed robust and durable anti-tumor activity and a well-tolerated safety profile in patients that enrolled at China sites who had advanced RET fusion-positive non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy.
Lead Product(s): Pralsetinib
Therapeutic Area: Oncology Product Name: BLU-667
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Blueprint Medicines
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 28, 2021
Details:
Developed by Blueprint Medicines, GAVRETO is a new therapy indicated for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer as detected by an FDA approved test. This agreement will continue Catalent’s involvement in the GAVRETO program.
Lead Product(s): Pralsetinib
Therapeutic Area: Oncology Product Name: Gavreto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Blueprint Medicines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 23, 2020
Details:
GAVRETO demonstrated consistent clinical activity in patients across lines of therapy and regardless of RET mutation genotypes, including a high response rate in patients with gatekeeper mutations resistant to multi-kinase inhibitors.
Lead Product(s): Pralsetinib
Therapeutic Area: Oncology Product Name: Gavreto
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Genentech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2020
Details:
PANTHERx® Rare Pharmacy has been selected by Blueprint Medicines as a limited distribution partner for new drug GAVRETO™ (pralsetinib), which was granted accelerated approval for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer.
Lead Product(s): Pralsetinib
Therapeutic Area: Oncology Product Name: Gavreto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Blueprint Medicines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 14, 2020
Details:
U.S. Food and Drug Administration (FDA) has approved Gavreto™ (pralsetinib) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.
Lead Product(s): Pralsetinib
Therapeutic Area: Oncology Product Name: Gavreto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 04, 2020
Details:
Under the collaboration, Blueprint Medicines’ pralsetinib and precision therapy expertise will be combined with Roche’s global reach, personalised healthcare capabilities and cancer therapies portfolio.
Lead Product(s): Pralsetinib
Therapeutic Area: Oncology Product Name: BLU-667
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $1,680.0 million Upfront Cash: $775.0 million
Deal Type: Collaboration July 14, 2020
Details:
Pralsetinib was well-tolerated, and showed deep and durable clinical activity in Chinese patients with RET-fusion NSCLC who were enrolled in the global, registrational phase I/II ARROW trial.
Lead Product(s): Pralsetinib
Therapeutic Area: Oncology Product Name: BLU-667
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 09, 2020
Details:
Pralsetinib is an investigational, once-daily precision therapy designed to potently and selectively inhibit RET fusions and mutations, including predicted resistance mutations.
Lead Product(s): Pralsetinib
Therapeutic Area: Oncology Product Name: BLU-667
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2020
Details:
The companies will co-develop and commercialize companion diagnostics (CDx) for pralsetinib, an investigational treatment developed by CStone’s partner Blueprint Medicines, in China for the detection of RET alterations in cancer patients.
Lead Product(s): Pralsetinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CStone Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 29, 2020
Details:
Blueprint Medicines plans to present updated clinical data for pralsetinib in RET-altered cancers and avapritinib in systemic mastocytosis. The data support the rapid clinical advancement of pralsetinib and avapritinib.
Lead Product(s): Pralsetinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
Details:
The approval is supported by new clinical trial results that showed three in five lung cancer patients with a certain genetic profile responded to the drug.
Lead Product(s): Pralsetinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
